로딩 중…
StockDiggingStockDigging

Medtronic plc

MDT· NYSE
IEIE
$96.56-0.57%
2026-10-30

Financials

Valuation Metrics

Medtronic plc's Market Cap is $123.97B. At end of 2025 it was $123.16B. Ranked #125 of 3,116 in US market (top 4%), #85 of 1,644 on NYSE (top 5%), #6 of 203 in Health Care Equipment & Services (top 3%) by Market Cap.

Investment Metrics(as of 2026-10-30)

MetricValue
Size
Market Cap$123.97B
Revenue$37.54B
Net Income$5.23B
Total Assets$93.31B
Net Assets$50.23B
Employees95,000
Value
P/E23.70x
P/B2.47x
PEG1.94x
P/S3.30x
EV/EBITDA15.92x
FCF Yield4.95%
Profitability
ROE10.41%
ROA5.61%
Op. Margin18.08%
Revenue Growth9.77%
Earnings Growth12.21%
Financial Health
Debt Ratio84.52%
Total Debt$28.15B
FCF$6.13B
Cash$1.69B
Current Ratio2.07x
Net Debt/EBITDA2.80x
Dividend
Div. Yield2.94%
Div. Growth8.63%
Performance
1Y Return6.92%
1M Return11.90%
From 52W High-8.53%
1Y MDD-29.48%
Trading
Volume5,513,784 shares
Trading Value$535M
Per Share
EPS$4.07
BPS$39.13

Company Info

CEO Mr. Geoffrey Straub Martha
Employees 95,000
HQ Galway, Ireland

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.